New Risks for Pepcid

With Merck's failed bid to secure over-the-counter (OTC) status for Mevachor still fresh on my mind, a FDA report this week about labeling changes in drugs caught my attention. At the bottom of the report was a brief mention of the H2-receptor antagonist, Famotidine, better known by its OTC label Pepcid. The FDA will now require Pepcid to include for the following warning on its label: "Famotidine should not be used in patients experiencing difficult or painful swallowing, vomiting with...

Read the Full Article for Free!

You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy

Subscribe for FREE to the #1 Natural Health Newsletter or Login for Instant Access

Unlock censored health information that Google doesn't want you to read

Keep your privacy secure — we are one of the few websites that have banned all Google and Facebook scripts to help stop their surveillance capitalism

Get access to all of Dr. Mercola's health articles, E-books and special reports